MedTrace Logo

Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction

NCT05310968 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 970

Last updated 2026-01-13

No results posted yet for this study

Summary

Perforating artery territorial infarction (PAI) refers to a single ischemic lesion in a single perforating arterial territory and branch atheromatous disease (BAD) is an important type. BAD related stroke accounts for 10%-15% ischemic cerebral infarction and is closely related to early neurological deterioration (END). Among patients with single ischemic lesion in other study, dual antiplatelet (clopidogrel plus aspirin) did not significantly reduce the risk of recurrent stroke. The primary purpose of this study is to assess the efficacy and safety of tirofiban combined with aspirin versus placebo combined with aspirin in reducing the risk of stroke and END in patients with BAD.

Conditions

  • Branch Atheromatous Disease

Interventions

DRUG

Tirofiban hydrochloride sodium chloride injection

Day 1: Tirofiban will be given by bolus injection at 0.4ug/kg/min for the first 30 minutes, followed by a continuous infusion at 0.1ug/kg/min for the next 24 hours.

DRUG

Tirofiban hydrochloride sodium chloride injection placebo

Day 1: Tirofiban placebo will be injected at the same rate with experimental group.

DRUG

Aspirin

Day 1: Aspirin 100-300mg per day Day 2-90: Aspirin 100mg per day

Sponsors & Collaborators

  • GrandPharma (China) Co., Ltd.

    collaborator INDUSTRY

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yilong Wang, PhD，MD · Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-12
Primary Completion
2025-02-17
Completion
2025-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05310968 on ClinicalTrials.gov